377 related articles for article (PubMed ID: 26892184)
1. Ameliorating antipsychotic-induced weight gain by betahistine: Mechanisms and clinical implications.
Lian J; Huang XF; Pai N; Deng C
Pharmacol Res; 2016 Apr; 106():51-63. PubMed ID: 26892184
[TBL] [Abstract][Full Text] [Related]
2. Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways.
Lian J; Huang XF; Pai N; Deng C
Psychoneuroendocrinology; 2014 Oct; 48():77-86. PubMed ID: 24992721
[TBL] [Abstract][Full Text] [Related]
3. Betahistine co-treatment ameliorates dyslipidemia induced by chronic olanzapine treatment in rats through modulation of hepatic AMPKα-SREBP-1 and PPARα-dependent pathways.
Liu X; Lian J; Hu CH; Deng C
Pharmacol Res; 2015 Oct; 100():36-46. PubMed ID: 26218603
[TBL] [Abstract][Full Text] [Related]
4. Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model.
Deng C; Lian J; Pai N; Huang XF
J Psychopharmacol; 2012 Sep; 26(9):1271-9. PubMed ID: 22695490
[TBL] [Abstract][Full Text] [Related]
5. Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment.
Lian J; Huang XF; Pai N; Deng C
PLoS One; 2014; 9(8):e104160. PubMed ID: 25084453
[TBL] [Abstract][Full Text] [Related]
6. Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study.
Smith RC; Maayan L; Wu R; Youssef M; Jing Z; Sershen H; Szabo V; Meyers J; Jin H; Zhao J; Davis JM
Psychopharmacology (Berl); 2018 Dec; 235(12):3545-3558. PubMed ID: 30382354
[TBL] [Abstract][Full Text] [Related]
7. Betahistine decreases olanzapine-induced weight gain and somnolence in humans.
Barak N; Beck Y; Albeck JH
J Psychopharmacol; 2016 Mar; 30(3):237-41. PubMed ID: 26839321
[TBL] [Abstract][Full Text] [Related]
8. Effects of olanzapine and betahistine co-treatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density.
Lian J; Huang XF; Pai N; Deng C
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Dec; 47():62-8. PubMed ID: 23994047
[TBL] [Abstract][Full Text] [Related]
9. The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients.
Poyurovsky M; Pashinian A; Levi A; Weizman R; Weizman A
Int Clin Psychopharmacol; 2005 Mar; 20(2):101-3. PubMed ID: 15729086
[TBL] [Abstract][Full Text] [Related]
10. Risperidone-induced weight gain and reduced locomotor activity in juvenile female rats: The role of histaminergic and NPY pathways.
Lian J; De Santis M; He M; Deng C
Pharmacol Res; 2015; 95-96():20-6. PubMed ID: 25782398
[TBL] [Abstract][Full Text] [Related]
11. The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain.
He M; Deng C; Huang XF
CNS Drugs; 2013 Jun; 27(6):423-34. PubMed ID: 23640535
[TBL] [Abstract][Full Text] [Related]
12. Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination.
Poyurovsky M; Fuchs C; Pashinian A; Levi A; Weizman R; Weizman A
Psychopharmacology (Berl); 2013 Apr; 226(3):615-22. PubMed ID: 23239133
[TBL] [Abstract][Full Text] [Related]
13. Hypothalamic histamine H1 receptor-AMPK signaling time-dependently mediates olanzapine-induced hyperphagia and weight gain in female rats.
He M; Zhang Q; Deng C; Wang H; Lian J; Huang XF
Psychoneuroendocrinology; 2014 Apr; 42():153-64. PubMed ID: 24636512
[TBL] [Abstract][Full Text] [Related]
14. Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression.
Han M; Deng C; Burne TH; Newell KA; Huang XF
Psychoneuroendocrinology; 2008 Jun; 33(5):569-80. PubMed ID: 18358632
[TBL] [Abstract][Full Text] [Related]
15. The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?
Deng C; Weston-Green K; Huang XF
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):1-4. PubMed ID: 19922755
[TBL] [Abstract][Full Text] [Related]
16. Olanzapine-activated AMPK signaling in the dorsal vagal complex is attenuated by histamine H1 receptor agonist in female rats.
He M; Zhang Q; Deng C; Wang H; Huang XF
Endocrinology; 2014 Dec; 155(12):4895-904. PubMed ID: 25264935
[TBL] [Abstract][Full Text] [Related]
17. Chronic betahistine co-treatment reverses olanzapine's effects on dopamine D₂ but not 5-HT2A/2C bindings in rat brains.
Lian J; Huang XF; Pai N; Deng C
Prog Neuropsychopharmacol Biol Psychiatry; 2015 Jan; 56():75-80. PubMed ID: 25149912
[TBL] [Abstract][Full Text] [Related]
18. Time-dependent effects of olanzapine treatment on the expression of histidine decarboxylase, H1 and H3 receptor in the rat brain: The roles in olanzapine-induced obesity.
He M; Zhang Q; Deng C; Jin T; Song X; Wang H; Huang XF
Psychoneuroendocrinology; 2017 Nov; 85():190-199. PubMed ID: 28886461
[TBL] [Abstract][Full Text] [Related]
19. Olanzapine increases AMPK-NPY orexigenic signaling by disrupting H1R-GHSR1a interaction in the hypothalamic neurons of mice.
Chen X; Yu Y; Zheng P; Jin T; He M; Zheng M; Song X; Jones A; Huang XF
Psychoneuroendocrinology; 2020 Apr; 114():104594. PubMed ID: 32007669
[TBL] [Abstract][Full Text] [Related]
20. A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Betahistine to Counteract Olanzapine-Associated Weight Gain.
Barak N; Beck Y; Albeck JH
J Clin Psychopharmacol; 2016 Jun; 36(3):253-6. PubMed ID: 27028981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
